Rexahn Pharmaceuticals, Inc.
http://www.rexahn.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Rexahn Pharmaceuticals, Inc.
Biotechs Vie To Take The Lead In Autoimmune CAR-Ts
First clinical efficacy readouts from several biotech companies developing CAR-Ts for systemic lupus erythematosus will be unveiled at EULAR, though the level of competition may be unsustainable.
RxBar Helps Customers Lose Exes As Nutrition, Wellness Lines Find Target, Whole Foods Shelves
Target adds more than 1,000 wellness products to its shelves; Whole Foods has exclusive deal with InBlooom; and RxBar makes “ultimate breakup gift” promotion.
2023 Review: Chinese-Sponsored Phase III US Trials See Uptick
Companies from China single-handedly sponsored a total of eight Phase III clinical studies that included US sites in 2023 compared to six in 2022 - but the figure was still below the record of 11 in 2021.
LegoChem Brings Late Christmas Cheer With $1.7bn ADC Deal
LegoChem Biosciences has sealed yet another sizable out-licensing agreement with a global big pharma firm, this time with Janssen, underlining the continued keen global interest in ADCs.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Drug Delivery
- Site Specific
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
- Nanotechnology, Chips, etc.
-
Drug Discovery Technologies
- Bioinformatics
- Other Names / Subsidiaries
-
- Ocuphire Pharma, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice